Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 18/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 2/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 2/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.64 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31064954 | 1.00 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL18741078 | 0.85 | RIPK1 (0.74) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL28043442 | 0.85 | RIPK1 (0.74) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL18767004 | 0.84 | RIPK1 (0.72) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31064970 | 0.84 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31065006 | 0.84 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL24655593 | 0.83 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1778505 | 0.80 | RIPK1 (0.74) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL4765770 | 0.80 | RIPK1 (0.67) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL30472919 | 0.80 | ADORA2A (0.70) | RIPK1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1990343-A2 | Azaindoles | Aventis Pharma Limited (GB) | 2008-11-12 | — | — | EP | claimed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | claimed |
| US-20040198737-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-10-07 | — | — | US | claimed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | claimed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | claimed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | claimed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | claimed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | claimed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | claimed |
| US-20240116923-A1 | USE OF INDOLE, 6- AND 7-AZAINDOLE DERIVATIVES AS INHIBITORS OF FERROPTOSIS REGULATED CELL DEATH | SEABELIFE (FR) | 2024-04-11 | — | — | US | disclosed |
| CN-117529317-A | Use of indole, 6-and 7-azaindole derivatives as inhibitors of iron death-mediated cell death | 海洋生命公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4281070-A1 | USE OF INDOLE, 6- AND 7-AZAINDOLE DERIVATIVES AS INHIBITORS OF FERROPTOSIS REGULATED CELL DEATH | Seabelife (FR) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022157392-A1 | USE OF INDOLE, 6- AND 7-AZAINDOLE DERIVATIVES AS INHIBITORS OF FERROPTOSIS REGULATED CELL DEATH | SEABELIFE (FR) | 2022-07-28 | — | — | WO | disclosed |
| EP-3362449-B1 | SIBIRILINE DERIVATIVES FOR USE FOR PREVENTING AND/OR TREATING DISORDERS ASSOCIATED WITH CELLULAR NECROPTOSIS | INST NAT SANTE RECH MED (FR) | 2021-06-16 | — | — | EP | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198737-A1 | Azaindoles | CCNY, CCNO, CNKSR1 | RIPK1 2247/4885CCNB2 194/4885CDK1 8/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | RIPK1 1614/4885CCNB2 381/4885CDK1 5/4885 |
| US-20240116923-A1 | USE OF INDOLE, 6- AND 7-AZAINDOLE DERIVATIVES AS INHIBITORS OF FERROPTOSIS REGULATED CELL DEATH | AIFM2, SLC40A1, FECH | RIPK1 76/4885CCNB2 3377/4885CDK1 2114/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | RIPK1 1843/4885CCNB2 244/4885CDK1 13/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | RIPK1 278/4885CCNB2 1015/4885CDK1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.